Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 22, 2007

Javelin Pharmaceuticals Signs Supply Pact with Baxter Healthcare

  • Baxter Healthcare inked a commercial supply agreement with Javelin Pharmaceuticals to provide additional manufacturing capacity for Javelin's injectable diclofenac, Dyloject™.

    Dylojectinjectable diclofenac sodium is under review for marketing approval in the U.K. for the treatment of acute moderate-to-severe pain. In the U.S., Dyloject is in Phase III trials for the same indication.

    Baxter will serve as a secondary manufacturer of Dyloject pending regulatory approval. The deal, which supplements an existing collaboration, has a three-year, renewable term and sets forth minimum purchase and production requirements.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »